Zhejiang Ausun Pharmaceutical Co., Ltd.

SHSE:603229 Stock Report

Market Cap: CN¥8.3b

Zhejiang Ausun Pharmaceutical Past Earnings Performance

Past criteria checks 2/6

Zhejiang Ausun Pharmaceutical has been growing earnings at an average annual rate of 30.2%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 21% per year. Zhejiang Ausun Pharmaceutical's return on equity is 11.2%, and it has net margins of 30.8%.

Key information

30.2%

Earnings growth rate

28.4%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate21.0%
Return on equity11.2%
Net Margin30.8%
Next Earnings Update30 Apr 2025

Recent past performance updates

Recent updates

Is Zhejiang Ausun Pharmaceutical (SHSE:603229) Using Too Much Debt?

Dec 20
Is Zhejiang Ausun Pharmaceutical (SHSE:603229) Using Too Much Debt?

There's No Escaping Zhejiang Ausun Pharmaceutical Co., Ltd.'s (SHSE:603229) Muted Earnings Despite A 37% Share Price Rise

Oct 08
There's No Escaping Zhejiang Ausun Pharmaceutical Co., Ltd.'s (SHSE:603229) Muted Earnings Despite A 37% Share Price Rise

Improved Earnings Required Before Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) Shares Find Their Feet

Jul 31
Improved Earnings Required Before Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) Shares Find Their Feet

Improved Earnings Required Before Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) Stock's 27% Jump Looks Justified

Mar 06
Improved Earnings Required Before Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) Stock's 27% Jump Looks Justified

Revenue & Expenses Breakdown

How Zhejiang Ausun Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SHSE:603229 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2483525811268
30 Jun 2484027410871
31 Mar 2480025012677
31 Dec 2381725411878
30 Sep 2385828412588
30 Jun 2385227314286
31 Mar 2382225812278
31 Dec 2276523511867
30 Sep 2271821311072
30 Jun 226651869464
31 Mar 226311738464
31 Dec 215701468369
30 Sep 215371317657
30 Jun 214851176650
31 Mar 214741106952
31 Dec 20409876351
30 Sep 20406727161
30 Jun 20389786967
31 Mar 20329706055
31 Dec 19308565748
30 Sep 19293624941
30 Jun 19257515036
31 Mar 19252504837
31 Dec 18244444534
30 Sep 18255544834
30 Jun 18266523244
31 Mar 18251433835
31 Dec 17240534130
30 Sep 17217553819
30 Jun 1721662530
31 Mar 1719758480
31 Dec 1619957480
31 Mar 1625962650
31 Dec 1526361650
31 Dec 1420122740

Quality Earnings: 603229 has high quality earnings.

Growing Profit Margin: 603229's current net profit margins (30.8%) are lower than last year (33%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 603229's earnings have grown significantly by 30.2% per year over the past 5 years.

Accelerating Growth: 603229's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 603229 had negative earnings growth (-9.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).

Return on Equity

High ROE: 603229's Return on Equity (11.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 23:27
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zhejiang Ausun Pharmaceutical Co., Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Feifei XuChina Merchants Securities Co. Ltd.
Kai WangCitic Securities Co., Ltd.
Jiaxi XuIndustrial Securities Co. Ltd.